FDA has granted priority review for Boehringer Ingelheim’s zongertinib NDA for treating unresectable or metastatic NSCLC.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

Alembic reported a 163% surge in consolidated net profit to Rs 26.09 crore, on a 47.3% jump in revenue from operations to Rs 57.92 crore in Q3 FY25 over Q3 FY24.

U.S. President Donald Trump has repeatedly mentioned pharmaceuticals as another industry that could be targeted by tariffs, but such measures would do little to lower drug prices south of the border, ...

Global investment giant TPG Group is set to expand its footprint in India’s pharmaceutical packaging ... is currently under review by the Competition Commission of India (CCI) for regulatory ...

The trade-off between affordability and availability in pharmaceuticals arises because decisions affecting medicines’ prices also impact their market availability. Higher prices can increase supply by ...

The National Law Review is a free-to-use, no-log-in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite facing operating loss and margin pressures.